How 8 Things Will Change The Way You Approach January

Psychedelic drug Wikipedia

Here, Kometer et al. assessed the ability to recognize the emotional state of another person from facial cues. They also quantified response selection and inhibition to emotional cues by behavioral and event-related EEG measurements in an emotional go/no-go task. In this test, 36 black-and-white photographs of the eye region of persons expressing different subtle emotional states were presented on a computer screen along with four words describing the states of the persons. Psychedelic Participants were instructed to choose the word that most accurately described the state of the person. In the emotional go/no-go task, emotionally valenced words were presented in the middle of the computer screen. Participants were instructed by text appearing at the beginning of each block to press as rapidly as possible a response button when words of one valence category were presented and withhold responses to words of another valence category (no-go cues).

Yet this term has remained popular with the public and even appears to be gaining popularity. As I intend to show in this discussion, however, the idea that psychedelics may have useful properties is not at all farfetched, and very recent clinical studies have reinforced the belief by many that psychedelics are well worth studying from a number of different perspectives. Indeed, one of the most striking developments in this field has been the initiation and successful completion of a variety of clinical studies of psychedelics in the past 15 years, most of which have been targeted to specific medical indications.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

The results suggest that the 5-HT2A receptor may be functionally expressed to regulate mechanisms underlying osteoblast cell proliferation, at least in part through activation of ERK/MAPK pathways in these cells. In mice, administration of 1 mg/kg DOI led to immune response suppression and reduction of spleen and peripheral blood CD8(+) T cell counts, with the cytotoxic/suppressor function (Davydova et al., 2010). These data also demonstrate the mediation of the serotonin 5-HT2A receptor in the immune response. Furrer et al. identified markers of hepatocyte proliferation 48 hours after mouse hepatectomy, as well as the mitotic index at 4 days. Both markers were dramatically decreased in cell proliferation in 2-year-old mice, and the mitotic index also was significantly decreased in old compared with young (7- to 8-week-old) mice.

These authors used the mouse hotplate test to insure that the effect was not due simply to analgesia produced by DOI. In a further study, Ripoll et al. used 5-HT2A–selective and 5-HT2B/C–selective antagonists to examine the receptor type involved in the anxiolytic effect of DOI. Only the 5-HT2A–selective antagonist blocked the DOI-induced antipunishment effect, suggesting that the anxiolytic effect of DOI was mediated through the 5-HT2A receptor. The authors discuss many possible mechanisms whereby 5-HT2A receptor activation could affect other neurotransmitter systems known to be involved in anxiety, such as GABA or noradrenergic pathways, but the mechanism through which DOI exerts an anxiolytic effect remains to be elucidated. Within the fly brain, there is a high density of serotonergic processes as well as 5-HT1A–like receptors in the visual centers of the fly brain that mediate visual processing (Luo et al., 2012). One behavior mediated by these areas is the optomotor response, or the ability of a fly to track and follow a moving object.

MDMA binds to the serotonin receptors, including the 5-HT2A receptors, which are responsible for producing hallucinations from classical psychedelics. The hallucination effects of MDMA are much milder than most of the other psychedelics on this list unless used at very high doses. Tagliazucchi et al. carried out a reanalysis of the previously published data from Carhart-Harris et al. .

Their reviews were based on reports from supervised clinical studies using pure drugs, so the same conclusions might not apply to recreational use of drugs with unknown identities or purity. By way of illustration, in 1952, there were only 10 publications in the National Library of Medicine concerning serotonin, nearly all of them dealing with some aspect of its ability to constrict blood vessels. Only 8 years later, in 1960, there were 300 publications on serotonin, 35 of which were now focused on studies of serotonin in the brain. For comparison, in 1960, there were only 197 publications about norepinephrine /noradrenaline, a neurotransmitter that had been discovered and studied in the mid-1940s.